Retatrutide, from Soma Chems , is receiving significant attention as a innovative therapy for obesity regulation. This innovative medication integrates the properties of a GLP-1 receptor agonist and a GIP receptor activator , aiming to not only promote metabolic improvements but also improve underlying metabolic issues . Preliminary clinical studie